What the session covered
In this session Daniela and Matteo Mosso worked through four real studies where enrolment had stalled or stopped, and explained how each was rescued. The first was a randomised post-market study for a legacy device facing an MDR deadline: four sites had enrolled two patients in three months. Marketing had chosen sites unfamiliar with trials, and a three-day exclusion window blocked recruitment. The team amended the protocol, added properly selected sites and reached 62 patients. The second, an IVD colorectal cancer study, had about 400 patients whose data sat in source documents and had not been entered into the CRF at one Spanish site. Two CRO changes had left monitoring and data transfer in disarray. Keeping the existing CRF, fixing the data flow and deploying two CRAs in parallel cleared the backlog and enrolment passed 1,300. The third, a US FDA study run in-house by an IVD company, had no clear ownership between European and US teams and began before statistical agreement with the FDA. A gap analysis led to a rewritten protocol, 18 sites and about 2,500 patients. The fourth, an implantable cardiovascular device, had seven active sites and no patients because investigators were reluctant about open heart surgery. Site visits, peer advocacy and animal training led to 45 patients. The common thread: sites are partners, not vendors; find the root cause early; and bring in outside eyes. They put delay costs at €1,000 to €7,000 per site per day.
Figures
Figures the speakers cited
Source: Daniela Carrera
Chapters
Jump to a moment
Times run from the start of the recording.
Take these with you
Six checks
Full recording
58:10Plays from YouTube when you press play. Cookie settings
How to cite this session
Carrera, D., Mosso, M., Sean (2026, August 19). When Enrollment Stops: Diagnosing a Study That's Already Gone Wrong [Webinar]. MedTech Leading Voice, MedTech Leading Voice. medtechleadingvoice.com/watch/2026-08-19-when-enrollment-stops-diagnosing-a-study-that-s-already-gone-wrong